骨化三醇治疗甲亢性骨质疏松症的疗效及其对OPG及RANKL水平的影响

Efficacy of calcitriol on hyperthyroidism osteoporosis and its effect on the levels of OPG and RANKL

目的探讨骨化三醇对甲亢性骨质疏松症的疗效及对其对患者血清护骨素(OPG)、细胞核因子κB受体活化因子配基(RANKL)水平的影响。方法将我院收治的58例甲亢性骨质疏松症患者随机分为对照组和观察组,各29例。对照组给予抗甲状腺药物联合双磷酸盐治疗,在此基础上,观察组给予骨化三醇治疗。比较两组临床疗效、骨密度、血清OPG及RANKL水平、不良反应发生率。结果观察组的治疗总有效率显著高于对照组(P<0.05)。治疗后,两组患者的骨密度均升高,血清OPG及RANKL水平均降低,且观察组均优于对照组(P<0.05)。观察组患者的不良反应总发生率显著低于对照组(P<0.05)。结论给予甲亢性骨质疏松症患者骨化三醇治疗,疗效确切,不良反应发生少,值得临床推广。

Objective To investigate the effect of calcitriol on hyperthyroidism osteoporosis and its effect on the levels ofserum osteoprotegerin （OPG） and nuclear factor-κB receptor activating factor ligand （RANKL）. Methods A total of 58hyperthyroidism osteoporosis patients enrolled in our hospital were randomly divided into control group （n =29） andobservation group （n=29）. The control group was given anti-thyroid drugs combined with bisphosphonate. On this basis, theobservation group was given calcitriol. The curative effects, bone mineral density, levels of serum OPG and RANKL,incidences of adverse reactions were compared between the two groups. Results The total effective rate of treatment in theobservation group was significantly higher than that in the control group（P〈0.05）. After treatment, the bone mineral densityof both groups increased, the levels of serum OPG and RANKL of both groups decreased, and those of the observationgroup were superior to the control group （P〈0.05）. The total incidence of adverse reactions in the observation group wassignificantly lower than that in the control group （P〈0.05）. Conclusion Calcitriol in the treatment of patients withhyperthyroidism osteoporosis has a definite curative effect and few adverse reactions. It is worthy of clinical promotion.